William H Matthai
Affiliation: University of Pennsylvania
- Evaluation of thrombocytopenia in the acute coronary syndromeWilliam H Matthai
Department of Medicine, University of Pennsylvania Medical School, Philadelphia, Pennsylvania 19104, USA
Curr Opin Hematol 17:398-404. 2010..Treatment strategies, both medical and mechanical, may cause thrombocytopenia. This review will introduce a differential diagnosis, diagnostic strategies, and treatment options for patients with an acute coronary syndrome...
- Safety and efficacy of argatroban in patients with heparin-induced thrombocytopeniaWilliam H Matthai
University of Pennsylvania Medical School, Penn Presbyterian Medical Center, Philadelphia, PA 19104, USA
Curr Hematol Rep 5:95-9. 2006..There is somewhat limited experience with its use in a number of other clinical scenarios in these patients. The current data on the use of argatroban in patients with HIT are reviewed...
- Treatment of heparin-induced thrombocytopenia in cardiovascular patientsWilliam H Matthai
Penn Presbyterian Medical Center, WS 392, Philadelphia, PA 19104, USA
Expert Opin Pharmacother 7:267-76. 2006..These agents and their use in cardiac patients, including patients with acute coronary syndrome, percutaneous coronary interventions, acute ST elevation myocardial infarction or cardiac surgery, will be reviewed...
- Thrombocytopenia in cardiovascular patients: diagnosis and managementWilliam H Matthai
University of Pennsylvania Medical Center Presbyterian, 39th and Market St, Philadelphia, PA 19104, USA
Chest 127:46S-52S. 2005..The use of a direct thrombin inhibitor in treatment should be considered early if a diagnosis of heparin-induced thrombocytopenia is possible...
- Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopeniaWilliam H Matthai
University of Pennsylvania Medical School, 39th and Market Sts WS 392, Philadelphia, PA 10104, USA
Thromb Res 116:121-6. 2005..We evaluated the safety and efficacy of argatroban, a direct thrombin inhibitor, as an anticoagulant in patients with a history of HIT needing acute anticoagulation...
- Evaluating the etiology of mechanical valve obstruction: use of clinical parameters, fluoroscopy, and echocardiographyAnthony Licata
Division of Cardiovascular Medicine, University of Pennsylvania Medical School, Philadelphia, Pennsylvania 19104, USA
Catheter Cardiovasc Interv 55:495-500. 2002..Clinical evaluation and diagnostic evaluation with fluoroscopy and echocardiography in distinguishing pannus from thrombus are reviewed...
- Effective management of acute coronary thrombosis in a young woman with lupus using aggressive medical therapyParin J Patel
Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Cardiology 118:45-9. 2011..Assessing clinical risk factors and using technologies such as intravascular ultrasound can help make the correct treatment decision...
- One-year clinical outcomes of protected and unprotected left main coronary artery stentingMichael P Kelley
Hospital of the University of Pennsylvania, University Health System, 9 Gates, 3400 Spruce Street, Philadelphia, PA 19104, USA
Eur Heart J 24:1554-9. 2003..Stenting for unprotected LMCA disease in a high-risk population should only be considered in the absence of other revascularization options. Further studies are needed to evaluate the role of stenting for unprotected LMCA disease...
- Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopeniaBruce E Lewis
Loyola University Medical Center, Maywood, Illinois, USA
Catheter Cardiovasc Interv 57:177-84. 2002..Overall, outcomes were comparable with those historically reported for heparin. Argatroban therefore is a reasonable anticoagulant option in this setting, where current options are limited...
- Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot studyIk Kyung Jang
Cardiology Division, Gray Bigelow 800, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
J Thromb Thrombolysis 18:31-7. 2004..This multicenter, prospective pilot study evaluated the efficacy and safety of argatroban in combination with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention...
- Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary interventionJorge R Kizer
Division of Cardiology, Department of Medicine and Public Health, Weill Medical College of Cornell University, New York, NY, USA
Eur Heart J 24:1314-22. 2003..Whether the prognostic significance of smaller post-procedural TnT elevations extends beyond the intermediate-term awaits further investigation...